Apellis Pharmaceuticals, Inc. (APLS)
After hours:
| Previous Close | 42.00 |
| Open | 42.00 |
| Bid | 41.27 x 600 |
| Ask | 41.35 x 300 |
| Day's Range | 41.16 - 42.42 |
| 52 Week Range | 19.83 - 94.75 |
| Volume | |
| Avg. Volume | 1,461,991 |
| Market Cap | 5.014B |
| Beta (5Y Monthly) | 0.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.43 |
| Earnings Date | Jul 29, 2024 - Aug 02, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 80.13 |
GlobeNewswireApellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
Apellis received $375 million in funding at close, with ability to access an additional $100 millionMajority of initial proceeds used to buy out existing SFJ Pharmaceuticals development liability Significantly improves liquidity profile by eliminating $366 million in SFJ payments through 2027 WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that it has entered into a non-dilutive, senior secured credit facility with Sixth Street, a le
Simply Wall St.Analysts Are Updating Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates After Its First-Quarter Results
There's been a notable change in appetite for Apellis Pharmaceuticals, Inc. ( NASDAQ:APLS ) shares in the week since...
Insider MonkeyApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript May 7, 2024 Apellis Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.54 EPS, expectations were $-0.54. Apellis Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good […]
